VIVALIS RECEIVES PRIZE FOR INVESTOR RELATIONS

VIVALIS RECEIVES PRIZE FOR INVESTOR RELATIONS

Nantes, Lyon (France) - November 28^th, 2012 - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today that it has been awarded the Prix de la Relation Actionnaires  (Prize for Investor Relations) in the Small Caps category.  Organized by the Les Echos Group and Mazars, in the presence of Jérôme Cazuhac, Budget Secretary of State for France, this prize rewards listed companies in Paris with the best practices for financial communication towards retail and institutional investors.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, " We are very proud to receive the Prix de la Relation Actionnaires. Our listing has given us the ability to transform and evolve from a young innovative SME into an international actor, which EB66® technology is now a reference for the production of vaccines. This success results from the unique expertise of our teams as well as the support of our shareholders that choose to trust us. We owe them a financial communication of quality. This is a commitment that applies to all our shareholders regardless of their size, location, and how long they have been with us. This prize is the opportunity to thank all our shareholders again for their support and to reiterate VIVALIS' aggressive ambitions.  These ambitions will come with financial communications that are always more proactive ."

********************

Next Financial Press Release

January 15^th, 2013, after NYSE Euronext market closing:
2013 Financial calendar

About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:

1. EB66^® Cell Line

               Vivalis offers research and commercial licenses for its EB66^® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66^® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66® cells received market approval in Japan for use in animal health.   Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales.

1. VIVA|Screen(TM) Human Antibody Discovery Platform

               Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.

               Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts